Epilepsy in the elderly;Epilepsia en ancianos

Revista de Neurologia

Volumn 42, Issue 1, 2006, Pages 42-46

  Poza Aldea, Juan José ^a  

^a HOSPITAL DONOSTIA   (Spain)

Author keywords

Antiepileptic drugs; Elderly; Epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; PREGABALIN;

CLINICAL FEATURE; COGNITIVE DEFECT; DRUG EFFECT; DRUG METABOLISM; EPILEPSY; GERIATRIC CARE; HUMAN; OSTEOPOROSIS; POLYPHARMACY; PROGNOSIS; REVIEW; SIDE EFFECT; WEIGHT GAIN; ADULT; AGED; ARTICLE; BODY WEIGHT; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BODY WEIGHT; EPILEPSY; HUMANS; MIDDLE AGED; PROGNOSIS;

EID: 33645557996     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4201.2005292     Document Type: Review

References (38)

1. Hauser WA. Seizure disorders: the changes with age. Epilepsia 1992; 33 (Suppl 4): S6-14.
2. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34: 453-68.
3. Tallis R, Hall G, Craig I, Dean A. How common are epileptic seizures in old age? Age Ageing 1991; 20: 442-8.
4. Loiseau J, Loiseau P, Duche B, Guyot M, Dartigues JF, Aublet B. A survey of epileptic disorders in southwest France: seizures in elderly patients. Ann Neurol 1990; 27: 232-7.
5. Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patients with epilepsy. Neurology 2004; 62 (Suppl 2): S24-9.
6. Pryor FM, Ramsay RE, Rowan AJ. Epilepsy in older adults: update from VA Cooperative Study no. 428. Epilepsia 2002; 43 (Suppl 7) 165-6.
7. Hiyoshi T, Yagi K. Epilepsy in the elderly. Epilepsia 2000; 41 (Suppl 9): S31-5.
8. Asconape JJ, Penry JK. Poststroke seizures in the elderly. Clin Geriatr Med 1991; 7: 483-92.
9. Ng SK, Hauser WA, Brust JC, Susser M. Hypertension and risk of new-onset unprovoked seizures. Neurology 1993; 43: 425-8.
10. Cleary P, Shorvon S, Tallis R. Late-onset seizures as a predictor of subsequent stroke. Lancet 2004; 363: 1184-6.
11. Bergey GK. Initial treatment of epilepsy. Special issues in treating the elderly. Neurology 2004; 63 (Suppl 4): S40-8.
12. Serrano Castro PJ, Ramos Lizana J, Pita-Calandre E, Camino-León R, Galán-Barranco JM, Rufo-Campos M, et al. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: I. Criterios de inicio y cese y bases farmacológicas del tratamiento antiepiléptico. Rev Neurol 2005; 40: 563-71.
13. Serrano Castro PJ, Casado-Chocán JL, Mercadé-Cerdá JM, Altuzarra-Corral A, Rufo-Campos M, Moreno-Alegre V, et al. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: III. Tratamiento antiepiléptico en situaciones especiales. Rev Neurol 2005; 40: 683-95.
14. Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004; 62: 2051-7.
15. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003; 17: 781-91.
16. Easter D, O'Bryan-Tear CG, Verity C. Weight gain with valproate or carbamazepine: a reappraisal. Seizure 1997; 6: 121-5.
17. De Toledo JC, Toledo C, De Cerce J, Ramsay RE. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997; 19: 394-6.
18. Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, et al; for the Pregabalin 1008-011 International Study Group. Pregabalin addon treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004; 45: 20-7.
19. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003; 11: 556-62.
20. Devinsky O, Vuong A, Hammer A, Barreto PS. Stable weight during lamotrigina therapy: a review of 32 studies. Neurology 2000; 54: 973-5.
21. Gidal BE, Sheth RD, Magnus L, Herbeuval AF. Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. Epilepsy Res 2003; 56: 121-6.
22. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42: 1255-60.
23. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145-51.
24. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study no. 264 Group. N Engl J Med 1992; 327: 765-71.
25. Brodie MJ, Chadwick DW, Anhut H, Otte A, Messmer SL, Maton S, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002; 43: 993-1000.
26. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37: 81-7.
27. Sánchez-Álvarez JC, Galán-Barranco JM, Camino-León R, Pita-Calandre E, Ramos Lizana J, Moreno-Alegre V, et al. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: II. Terapéutica antiepiléptica crónica en el adulto y en el niño. Rev Neurol 2005; 40: 619-26.
28. Birnbaum A, Hardie NA, Leppik IE, Conway JM, Bowers SE, Lackner T, et al. Variability of total phenytoin serum concentrations within elderly nursing home residents. Neurology 2003; 60: 555-9.
29. Kutluay E, McCague K, D'Souza J, Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 2003; 4: 175-80.
30. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults Epilepsia 2000; 41 (Suppl 1): S66-71.
31. Anderson GD, Gidal BE, Messenheimer JA, William FG. Time course of lamotrigine deinduction: impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Res 2002; 49: 211-7.
32. Gidal BE, Sheth R, Parnell J, Maloney K, Sale M. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. Epilepsy Res 2003; 57: 85-93.
33. Gil-Nagel A, Gómez Alonso J. Experiencia clínica de la pregabalina en el tratamiento de las epilepsias focales. Rev Neurol 2005; 40: 609-13.
34. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabaline adjunctive therapy in patients with partial seizures. Neurology 2003; 60: 1631-7.
35. Brodie MJ. Pregabalin as adjunctive therapy for partial seizures. Epilepsia 2004; 45 (Suppl 6): S19-27.
36. Ferrendelli JA, French J, Leppik I, Morrell MJ, Herbeuval A, Han J, et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset análisis of the KEEPER trial. Epilepsy Behav 2003; 4: 702-9.
37. Morrell MJ, Leppik I, French J, Ferrendelli J, Han J, Magnus L. The KEEPER trial levetiracetam adjunctive treatment of partial-onset seizures in an open label community-based study. Epilepsy Res 2003; 54: 153-61.
38. White JR, Walzack TS, Leppik IE, Rarick J, Tran T, Beniak TE, et al. Discontinuation of levetiracetam because of behavioural side effects: a case control study. Neurology 2003; 61: 1218-21.